Text size: A A A


  • 1. Jetrea Summary of Product Characteristics. ThromboGenics NV. Belgium.
  • 2. Stalmans P, Benz MS, Gandorfer A, Kampik A, et al. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular hole. N Engl J Med. 2012;367:606-615.
  • 3. Gandorfer A, Rohleder M, Sethi C, et al. Posterior vitreous detachment induced by microplasmin. Invest Ophthalmol Vis Sci. 2004;45:641-647.
  • 4. De Smet MD, Valmaggia C, Zarranz-Ventura J, Willekens B. Microplasmin: ex vivo characterization of its activity in porcine vitreous. IOVS. 2009;50(2):814-819.
  • 5. Jaffe NS. Vitreous traction at the posterior pole of the fundus due to alterations in the vitreous posterior. Trans Am Acad Ophthalmol Otolaryngol. 1967;71(4):642-652.
  • 6. Reese AB, Jones IS, Cooper WC. Macular changes secondary to vitreous traction. Trans Am Ophthalmol Soc. 1966;64:123-134.
  • 7. Akiba J, Yoshida A, Trempe CL. Risk of developing a macular hole. Arch Ophthalmol. 1990;108:1088-1090.
  • 8. Sebag J, Wang MY. Combined spectral-domain optical coherence tomography/scanning laser ophthalmoscopy imaging of vitreous and the vitreo-retinal interface. In: Holz FG, Spaide RF, eds. Medical Retina: Focus on Retinal Imaging. Berlin, Germany: Springer-Verlag; 2010:157-168.
  • 9. Barak Y, Ihnen M, Schaal S. Spectral domain optical coherence tomography in the diagnosis and management of vitreoretinal interface pathologies. J Ophthalmol. 2012. doi:10.1155/2012/876472.
  • 10. Koerner F, Garweg J. Vitrectomy for macular pucker and vitreomacular traction syndrome. Doc Ophthalmol. 1999;97(3-4):449-458.
  • 11. Data on file, Clinical Overview. ThromboGenics, Inc., 2012.
  • 12. Data on file, OCT Scans. ThromboGenics, Inc., 2012.
  • 13. Carrero JL. Incomplete posterior vitreous detachment: prevalence and clinical relevance. Am J Ophthalmol. 2012;153(3):497-503.
  • 14. Hikichi T, Yoshida A, Trempe C. Course of vitreomacular traction syndrome. Am J Ophthalmol. 1995;119(1):55-61.
  • 15. Johnson MW. Posterior vitreous detachment: evolution and complications of its early stages. Am J Ophthalmol. 2010;149(3):371-382.
  • 16. Hirneiss C, Neubauer AS, Gass CA, et al. Visual quality of life after macular hole surgery: outcome and predictive factors. Br J Ophthalmol. 2007;91:481-484.
  • 17. Okamoto F, Okamoto Y, Fukuda S, Hiraoka T, Oshika T. Vision-related quality of life and visual function after vitrectomy for various vitreoretinal disorders. Invest Ophthalmol Vis Sci. 2010;51:744-751.
  • 18. American Academy of Ophthalmology Retinal Panel. Preferred Practice Pattern® Guidelines. Idiopathic Macular Hole. San Francisco, CA: American Academy of Ophthalmology; 2008. http://www.aao.org/ppp . Accessed October 24, 2012.
  • 19. Krebs I, Brannath W, Glittenberg C, Zeiler F, Sebag J, Binder S. Posterior vitreomacular adhesion: a potential risk factor for exudative age-related macular degeneration? Am J Ophthalmol. 2007;144(5):741-746.
  • 20. Ghazi NG, Ciralsky JB, Shah SM, Campochiaro PA, Haller JA. Optical coherence tomography findings in persistent diabetic macular edema: the vitreomacular interface. Am J Ophthalmol. 2007;144(5):747-754.
  • 21. Kim JW, Freeman WR, Azen SP, el-Haig W, Klein DJ, Bailey IL. Prospective randomized trial of vtrectomy or observation for stage 2 macular hole. Vitrectomy for Macular Hole Study Group. Am J Ophthalmol. 1996;121(6):605-614.
  • 22. Guyer DR, de Bustros S, Diener-West M, Fine SL. Observations on patients with idiopathic macular holes and cysts. Arch Ophthalmol. 1992;110:1264-1268.
  • 23. Chew EY, Sperduto RD, Hiller R, et al. Clinical course of macular holes. Arch Ophthalmol. 1999;117:242-246.
  • 24. Sugiyama A, Imasawa M, Chiba T, Lijima H. Reappraisal of spontaneous closure rate of idiopathic full-thickness macular holes. Open Ophthalmol J. 2012;6:73-74.
  • 25. Schneider EW, Johnson MW. Emerging nonsurgical methods for the treatment of vitreomacular adhesion: a review. Clin Ophthalmol. 2011;5:1151-1165.
  • 26. Bottos J, Elizade J, Arevalo JF, et al. Vitreomacular traction syndrome. Opthal Vis Research. 2012;7(2):148-161.
  • 27. Gallemore RP, Jumper JM, McCuen BW, Jaffe GJ, Postel EA, Toth CA. Diagnosis of vitreoretinal adhesions in macular disease with optical coherence tomography. Retina. 2000;20(2):115-120.
  • 28. Data on file, Summary of Clinical Efficacy. ThromboGenics, Inc., 2012.

Next: Home

Take action with JETREA® (ocriplasmin) Intravitreal (IVT) Injection

JETREA® Cross eye JETREA® Cross eye JETREA® Cross eye

A one-time injection of JETREA® has been shown to provide early resolution of vitreomacular traction, including when associated with macular hole of diameter ≤400 µm.1


Compare the anatomical evidence of JETREA®

Vitreomacular (VMT) OCT scan at Day 28 Vitreomacular (VMT) OCT scan at Day 28 Vitreomacular (VMT) OCT scan at Day 28

Landmark studies provide anatomical evidence for early pharmacologic resolution of vitreomacular traction.1,2,12


Learn about the impact of vitreomacular traction and macular hole on your patients

Metamorphopsia from a patient perspective Metamorphopsia from a patient perspective Metamorphopsia from a patient perspective

Vitreomacular traction and macular hole often result in visual impairment, particularly central vision loss.8,9


Important Safety Information

Indications: JETREA® is indicated in adults for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.

Dosage: JETREA® must be prepared and administered by a qualified ophthalmologist experienced in intravitreal injections. The recommended dose is 0.125 mg (0.1 mL of the diluted solution) administered by intravitreal injection to the affected eye once as a single dose.

Contraindications: JETREA® is contraindicated for use with patients who are hypersensitive to ocriplasmin or to any of the excipients in JETREA® (mannitol, citric acid, sodium hydroxide and water), or with patients who have active or suspected ocular or periocular infections.

Warnings and Precautions: Post-Injection Monitoring: Intravitreal injections have been associated with intraocular inflammation/infection, intraocular haemorrhage and increased intraocular pressure (IOP). Proper aseptic injection techniques must always be used. Following the intravitreal injection, patients should be monitored for any side effects such as (but not limited to) intraocular inflammation/infection and elevation in IOP. Other Warnings and Precautions: Administration of JETREA® to both eyes concurrently has not been studied, and is not recommended. Repeated administration of JETREA® in the same eye has not been studied, and is not recommended. There are no clinical data on the concomitant use of ocriplasmin with VEGF-inhibitors. JETREA® has not been studied in patients with large diameter macular holes (>400 microns), high myopia (>8 dioptre spherical correction or axial length >28 mm), aphakia, history of rhegmatogenous retinal detachment, lens zonule instability, recent ocular surgery or intraocular injection (including laser therapy), proliferative diabetic retinopathy, ischaemic retinopathies, retinal vein occlusions, exudative age-related macular degeneration (AMD) and vitreous haemorrhage; treatment is not recommended in these patients. The potential for lens subluxation or phacodonesis cannot be ruled out. There is limited experience in patients with non-proliferative diabetic retinopathy or in patients with a history of uveitis or significant eye trauma; caution should be exercised when treating such patients. The effect of ocriplasmin (particularly in inducing resolution of vitreomacular adhesion (VMA) or causing total posterior vitreous detachment (PVD) is reduced in subjects with an epiretinal membrane (ERM) or a diameter of VMA >1500 microns. Due to a potential increase in tractional forces, there is a risk of occurrence of new or enlarged macular holes. There is a risk for a significant, but transient loss of visual acuity during the first week after the injection; patients should be monitored appropriately.

Interactions: No formal interaction studies have been conducted.

Undesirable Effects: In the JETREA® clinical studies, all adverse reactions were ocular. Most of the adverse reactions occurred within the first week after the injection. The majority of these reactions were non-serious, mild in intensity and resolved within 2 to 3 weeks. The incidence of serious adverse reactions that occurred in all clinical studies was 2.2% in JETREA® treated patients and 2.4% in placebo-controlled patients. Very common (≥1/10) adverse reactions are: vitreous floaters, eye pain, and conjunctival haemorrhage. Common (≥1/100 to <1/10) adverse reactions are: visual acuity reduced, visual impairment, vision blurred, retinal haemorrhage, vitreous haemorrhage, retinal tear, retinal detachment, intraocular pressure increased,macular hole, macular degeneration, retinal degeneration, macular oedema, retinal oedema, retinal pigment epitheliopathy, metamorphopsia, vitreous adhesions, conjunctival oedema, eyelid oedema, vitritis, anterior chamber cell, anterior chamber flare, iritis, photopsia, conjunctival hyperaemia, ocular hyperaemia, vitreous detachment, retinogram abnormal, eye irritation, dry eye, foreign body sensation in eyes, eye pruritus, ocular discomfort, photophobia, and chromatopsia. Uncommon (≥1/1,000 to <1/100) are: transient blindness, lens subluxation, scotoma, visual field defect, diplopia, hyphaema, miosis, pupils unequal, corneal abrasion, anterior chamber inflammation, eye inflammation, and conjunctival irritation.

Click here to review the JETREA® Summary of Product Characteristics.